Serotonin and Dopamine Antagonism in Obsessive-Compulsive Disorder: Effect of Atypical Antipsychotic Drugs

 

 Buy Article Permissions and Reprints

Background: Previous reports suggest that some atypical antipsychotics may have obsessogenic as well as antiobsessional effects. Given their higher affinity for serotonin 5HT₂ receptors than dopamine D₂ receptors, it has been speculated that atypical antipsychotics may induce obsessive-compulsive (OC) symptoms, even at low doses, due to high 5HT₂ antagonism, whereas improvement in OC symptoms is thought to occur only at high doses due to high D₂ antagonism. Method: In this open case series, the dose-response relationship of atypical antipsychotic augmentation in the treatment of obsessive compulsive disorder (OCD), and the dose-severity relationship in atypical anti psychotic-induced OC symptoms were examined. Three patients were identified who had either refractory OCD or OC symptoms following administration of atypical antipsychotics such as olanzapine and risperidone. Results: Case 1: A linear dose-response relationship between increasing doses of olanzapine and improvement in OC symptoms was observed in an OCD patient resistant to 5-HT reuptake inhibitors. 2: OC symptoms induced by low doses of risperidone (1 mg) were reversed by increasing the doses of risperidone (3 mg) in a bipolar disorder patient suggesting an inverse dose-severity relationship. 3: No inverse dose-severity relationship was noted between olanzapine induced OC symptoms and its dosage in an asymptomatic OCD patient. Tretment-emergence OC symptoms responded to increasing the doses of maintanance clomipramine treatment. Conclusions: Controlled studies are needed to investigate the dose-response or dose-severity relationships between OCD and atypical antipsychotics.

References

• 1 Austin L S, Lydiard R B, Ballenger J C, Cohen B M, Laraia M T, Zealberg J J, Fossey M D, Ellinwood E H. Dopamine blocking activity of clomipramine in patients with obsessive compulsive disorder.  Biol Psychiatry. 1991;  30 225-232
  CrossrefPubMedGoogle Scholar
• 2 Baker R W, Chengappa K N R, Baird J W, Steingard S, Christ M A G, Schooler N R. Emergence of obsessive compulsive symptoms during treatment with clozapine.  J Clin Psychiatry. 1992;  53 439-442
  PubMedGoogle Scholar
• 3 Bymaster F P, Calligaro D D, Falcone J F, Marsh R D, Moore N A, Tye N C, Seeman P, Wong D T. Radioreceptor binding profile of the atypical antipsychotic olanzepine.  Neuropsychopharmacol. 1996;  14 87-96
  PubMedGoogle Scholar
• 4 Ceccherini-Nelli A, Guazzelli M. Treatment of refractory OCD with the Dopamine agonist Bromocriptine.  J Clin Psychiatry. 1994;  55 415-416
  PubMedGoogle Scholar
• 5 Delgado P L, Goodman W K, Price L H, Heninger G R, Charney D S. Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive compulsive disoder.  Br J Psychiatry. 1990;  157 762-765
  PubMedGoogle Scholar
• 6 Goodman W K, Price L H, Rasmussen S A, Delgado P L, Heninger G R, Charney D S. Efficacy of fluvoxamine in obsessive compulsive disorder: A double blind comparison with placebo.  Arch Gen Psychiatry. 1989;  46 36-44
  PubMedGoogle Scholar
• 7 Goodman W K, Price L H, Rasmussen S A, Mazure C, Fleischmann R L, Hill C L, Heninger G R, Charney D S. The Yale-Brown obsessive compulsive scale: Development, use, and reliability.  Arch Gen Psychiatry. 1989;  46 1006-1011
  PubMedGoogle Scholar
• 8 Goodman W K, Price L H, Delgado P L, Palumbo J, Krystal J H, Nagy L M, Rasmussen S A, Heninger G R, Charney D S. Specificity of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder: Comparison of fluvoxamine and desipramine.  Arch Gen Psychiatry. 1990;  47 577-585
  PubMedGoogle Scholar
• 9 Hewlett W A, Vinogrador S, Agras W S. Clomipramine, clonazepam and clonidine treatment of obsessive-compulsive disorder.  J Clin Psycho-pharmacol. 1992;  12 420-430
  PubMedGoogle Scholar
• 10 Knesevich J W. Successful treatment of obsessive-compulsive disorder with clonidine hydrochloride.  Am J Psychiatry. 1982;  139 364-365
  PubMedGoogle Scholar
• 11 Kopala L, Honer W G. Risperidone, serotonergic mechanisms and obsessive compulsive symptoms in schizophrenia (letter).  Am J Psychiatry. 1994;  5 1714-1715
  PubMedGoogle Scholar
• 12 Kapur S, Remington G, Zipursky R B, Wilson A A, Houle S. The D₂ dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.  Life Sci. 1995;  57 103-107
  CrossrefPubMedGoogle Scholar
• 13 Kapur S. A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Molecular.  Psychiatry. 1998;  3 135-140
  CrossrefPubMedGoogle Scholar
• 14 Kapur S, Zipursky R B, Remington G, Jones C, DaSilva J, Wilson A A, Houle S. 5HT₂ and D₂ receptor occupancy of olanzepine in schizophrenia: A PET investigation.  Am J Psychiatry. 1998;  155 921-928
  PubMedGoogle Scholar
• 15 Leysen J E, Janssen P M, Schotte A, Luyten W H, Megens A A. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT₂ receptors.  Psychopharmacol (Berl). 1993;  112 540-554
  PubMedGoogle Scholar
• 16 McDougle C J, Goodman W K, Price L H, Delgado P L, Krystal J H, Charney D S, Heninger G R. Neuroleptic addition in fluvoxamine-refractory obsessive compulsive disorder: an open case series.  Am J Psychiatry. 1990;  147 652-654
  PubMedGoogle Scholar
• 17 McDougle C J, Goodman W K, Leckman J F, Lee N C, Heninger G R, Price L H. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.  Arch Gen Psychiatry. 1994;  51 302-308
  CrossrefPubMedGoogle Scholar
• 18 Remington G, Adams M. Risperidone and obsessive compulsive symptoms (letter).  J Clin Psycho-pharmacol. 1994;  14 358-359
  PubMedGoogle Scholar
• 19 Saxena S, Wang D, Bystritsky A, Baxter Jr L R. Risperidone augmentation of SRI treatment for refractory obsessive compulsive disorder.  J Clin Psychiatry. 1996;  57 303-306
  PubMedGoogle Scholar
• 20 Schotte A, Janssen P F, Megens A A, Leysen J E. Occupancy of central neurotransmitter receptor by risperidone, clozapine and haloperidol measured in vivo by quantitative autoradiography.  Brain Res. 1993;  631 191-202
  CrossrefPubMedGoogle Scholar
• 21 Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial.  Clin Neuropharmacol. 1998;  21 176-180
  PubMedGoogle Scholar

R. Ramasubbu,M.D. 

Dept. of Psychiatry Royal Ottawa Hospital

1145 Carling Avenue

Ottawa, Ontario, K1Z 7K4

Canada

Phone: ++613-722-6521 ext. 7076

Fax: ++613-722-5048

Email: rramasub@rohcg.on.ca